New perspective for the treatment of Alzheimer diseases: Liposomal rivastigmine formulations

References

• Scarpini E, Scheltens P, Feldman H. (2003). Treatment of Alzheimer’s disease: current status and new perspectives. Lancet Neurol, 2:539–547.
   PubMed Web of Science ®Google Scholar
• Polinsky RJ. (1998). Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease. Clin Ther, 20:634–647.
   PubMed Web of Science ®Google Scholar
• Alloul K, Sauriol L, Kennedy W, Laurier C, Tessier G, Novosel S et al. (1998). Alzheimer’s disease: a review of the disease, its epidemiology and economic impact. Arch Gerontol Geriatr, 27:189–221.
   PubMed Web of Science ®Google Scholar
• Delagarza VW. (2003). Pharmacologic treatment of Alzheimer’s disesase: an update. Am Fam Phys, 68:1365–1372.
   PubMed Web of Science ®Google Scholar
• Smith MA, Perry G. (1998). What are the facts and artifacts of the pathogenesis and etiology of Alzheimer disease? J Chem Neuroanat, 16:35–41.
   PubMed Web of Science ®Google Scholar
• Standridge JB. (2004). Pharmacotherapeutic approaches to the treatment of Alzheimer’s disease. Clin Ther, 26:615–630.
   PubMed Web of Science ®Google Scholar
• Williams BR, Nazarians A, Gill MA. (2003). A review of rivastigmine: a reversible cholinesterase inhibitor. Clin Ther, 25:1634–1653.
   PubMed Web of Science ®Google Scholar
• Farlow MR, Lilly ML; ENA713 B352 Study Group. (2005). Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer’s disease for up to 5 years. BMC Geriatr, 5:3.
   PubMedGoogle Scholar
• Agid Y, Dubois B, Anand R,Gharabawi G. (1998). Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type. Curr Ther Res, 59:833–845.
   Google Scholar
• Yüksel N. (2000). Alzheimer hastalığının ilaçla tedavisi. Klin Psikiyatr, 3:137–141.
   Google Scholar
• Ercan S. (2002). Alzheimer hastalığı tedavisinde kullanılan kolinesteraz inhibitörleri. Demans, 2:5–9.
   Google Scholar
• Tse FL, Laplanche R. (1998). Absorption, metabolism, and disposition of [14C]SDZ ENA 713, an acetylcholinesterase inhibitor, in minipigs following oral, intravenous, and dermal administration. Pharm Res, 15:1614–1620.
   PubMed Web of Science ®Google Scholar
• Scherrman JM. (2002). Drug delivery to brain via the blood-brain barrier. Vasc Pharmacol, 38:349–354.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. (2007). Blood-brain barrier delivery. Drug Discov Today, 12:54–61.
   PubMed Web of Science ®Google Scholar
• Jeffrey P, Summerfield SG. (2007). Challenges for blood-brain barrier (BBB) screening. Xenobiotica, 37:1135–1151.
   PubMed Web of Science ®Google Scholar
• Gumbleton M, Audus KL. (2001). Progress and limitations in the use of in vitro cell cultures to serve as a permeability screen for the blood-brain barrier. J Pharm Sci, 90:1681–1698.
   PubMed Web of Science ®Google Scholar
• Hawkins RA, O’Kane RL, Simpson IA, Viña JR. (2006). Structure of the blood-brain barrier and its role in the transport of amino acids. J Nutr, 136:218S–226S.
   PubMed Web of Science ®Google Scholar
• Lundquist S, Renftel M, Brillault J, Fenart L, Cecchelli R, Dehouck MP. (2002). Prediction of drug transport through the blood-brain barrier in vivo: a comparison between two in vitro cell models. Pharm Res, 19:976–981.
   PubMed Web of Science ®Google Scholar
• Braun A, Hämmerle S, Suda K, Rothen-Rutishauser B, Günthert M, Krämer SD et al. (2000). Cell cultures as tools in biopharmacy. Eur J Pharm Sci, 11 Suppl 2:S51–S60.
   PubMed Web of Science ®Google Scholar
• Wilson G. (1990). Cell culture techniques for the study of drug transport. Eur J Drug Metab Pharmacokinet, 15:159–163.
   PubMed Web of Science ®Google Scholar
• Lemaire M, Desrayaund S. (2005). The priorities/needs of the pharmaceutical industry in drug delivery to the brain. Int Cong Ser, 1277:32–46.
   Google Scholar
• Garberg P, Ball M, Borg N, Cecchelli R, Fenart L, Hurst RD et al. (2005). In vitro models for the blood-brain barrier. Toxicol in Vitro, 19:299–334.
   PubMed Web of Science ®Google Scholar
• Degim Z, Mutlu NB, Yilmaz S, Essiz D, Nacar A. (2010). Investigation of liposome formulation effects on rivastigmine transport through human colonic adenocarcinoma cell line (CACO-2). Pharmazie, 65:32–40.
   PubMed Web of Science ®Google Scholar
• Shah P, Jogani V, Mishra P, Mishra AK, Bagchi T, Misra A. (2008). In vitro assessment of acyclovir permeation across cell monolayers in the presence of absorption enhancers. Drug Dev Ind Pharm, 34:279–288.
   PubMed Web of Science ®Google Scholar
• Wen H, Watry DD, Marcondes MC, Fox HS. (2004). Selective decrease in paracellular conductance of tight junctions: role of the first extracellular domain of claudin-5. Mol Cell Biol, 24:8408–8417.
   PubMedGoogle Scholar
• Shi LZ, Zheng W. (2005). Establishment of an in vitro brain barrier epithelial transport system for pharmacological and toxicological study. Brain Res, 1057:37–48.
   PubMed Web of Science ®Google Scholar
• Alavijeh MS, Chishty M, Qaiser MZ, Palmer AM. (2005). Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery. Neurorx, 2:554–571.
   PubMedGoogle Scholar
• Micklus MJ, Greig NH, Tung J, Rapoport SI. (1993). Targetting of liposomes to the blood-brain barrier in rats. Drug Deliv, 1:21–26.
   Google Scholar
• Uhumwango MU, Okor RS. (2005). Current trends in the production and biomedical applications of liposomes: a review. J Med Biomed Res, 4:9–21.
   Google Scholar
• Lasic DD. (1998). Novel applications of liposomes. Trends Biotechnol, 16:307–321.
   PubMed Web of Science ®Google Scholar
• Degim Z. (2008). Use of microparticulate systems to accelerate skin wound healing. J Drug Target, 16:437–448.
   PubMed Web of Science ®Google Scholar
• Alemdaroglu C, Degim Z, Celebi N, Sengezer M, Alömeroglu M, Nacar A. (2008). Investigation of epidermal growth factor containing liposome formulation effects on burn wound healing. J Biomed Mater Res A, 85:271–283.
   PubMed Web of Science ®Google Scholar
• Degim Z, Unal N, Essiz D, Abbasoglu U. (2004). The effect of various liposome formulations on insulin penetration across Caco-2 cell monolayer. Life Sci, 75:2819–2827.
   PubMed Web of Science ®Google Scholar
• Allen TM. (1997). Liposomes. Opportunities in drug delivery. Drugs, 54 Suppl 4:8–14.
   PubMed Web of Science ®Google Scholar
• Rao BM, Srinivasu MK, Kumar KP, Bhradwaj N, Ravi R, Mohakhud PK et al. (2005). A stability indicating LC method for rivastigmine hydrogen tartrate. J Pharm Biomed Anal, 37:57–63.
   PubMed Web of Science ®Google Scholar
• El-Gazayerly ON, Hikal AH. (1997). Preparation and evaluation of acetazolamide liposomes as an ocular delivery system. Int J Pharm, 158:121–127.
   Web of Science ®Google Scholar
• Li H, Song JH, Park JS, Han K. (2003). Polyethylene glycol-coated liposomes for oral delivery of recombinant human epidermal growth factor. Int J Pharm, 258:11–19.
   PubMed Web of Science ®Google Scholar
• Cong W, Liu Q, Chen X, Gao R, Lu J, Wang Y et al. (2010). Characterization and pharmacokinetics of a novel pirarubicin liposome powder. Drug Dev Ind Pharm, 36:1186–1194.
   PubMed Web of Science ®Google Scholar
• Yeh YH, Hwang DF. (2001). High-performance liquid chromatographic determination for bile components in fish, chicken and duck. J Chromatogr B Biomed Sci Appl, 751:1–8.
   PubMedGoogle Scholar
• Basappa C, Rao P, Rao DN, Divakar S. (1998). A modified colorimetric method for the estimation of β-cyclodextrin using phenolphthalein. Int J Food Sci Tech, 33:517–520.
   Web of Science ®Google Scholar
• Mosmann T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods, 65:55–63.
   PubMed Web of Science ®Google Scholar
• Raiman J, Törmälehto S, Yritys K, Junginger HE, Mönkkönen J. (2003). Effects of various absorption enhancers on transport of clodronate through Caco-2 cells. Int J Pharm, 261:129–136.
   PubMed Web of Science ®Google Scholar
• Zerrouk N, Corti G, Ancillotti S, Maestrelli F, Cirri M, Mura P. (2006). Influence of cyclodextrins and chitosan, separately or in combination, on glyburide solubility and permeability. Eur J Pharm Biopharm, 62:241–246.
   PubMed Web of Science ®Google Scholar
• Meaney CM, O’Driscoll CM. (2000). A comparison of the permeation enhancement potential of simple bile salt and mixed bile salt:fatty acid micellar systems using the CaCo-2 cell culture model. Int J Pharm, 207:21–30.
   PubMed Web of Science ®Google Scholar
• Duplay D. (2004). Physicians’ Desk Reference, 58th edn. Montvale: Thomson PDR, pp. 2252–2260.
   Google Scholar
• Enz A, Gentsch C. (2004). Co-administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain. Neuropharmacology, 47:408–413.
   PubMed Web of Science ®Google Scholar
• Geerts H, Guillaumat PO, Grantham C, Bode W, Anciaux K, Sachak S. (2005). Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits. Brain Res, 1033:186–193.
   PubMed Web of Science ®Google Scholar
• Ellman GL, Courtney KD, Andres V Jr, Feather-Stone RM. (1961). A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol, 7:88–95.
   PubMed Web of Science ®Google Scholar
• Begley DJ, Bradbury MW, Kreuter J. (2000). The blood-brain barrier and drug delivery to the CNS. New York: Marcel Dekker.
   Google Scholar
• Fagerholm U. (2007). The highly permeable blood-brain barrier: an evaluation of current opinions about brain uptake capacity. Drug Discov Today, 12:1076–1082.
   PubMed Web of Science ®Google Scholar
• Sakamoto A, Ido T. (1993). Liposome targeting to rat brain: effect of osmotic opening of the blood-brain barrier. Brain Res, 629:171–175.
   PubMed Web of Science ®Google Scholar
• Visser CC, Stevanovic S, Voorwinden LH, van Bloois L, Gaillard PJ, Danhof M et al. (2005). Targeting liposomes with protein drugs to the blood-brain barrier in vitro. Eur J Pharm Sci, 25:299–305.
   PubMed Web of Science ®Google Scholar
• Arumugam K, Subramanian GS, Mallayasamy SR, Averineni RK, Reddy MS, Udupa N. (2008). A study of rivastigmine liposomes for delivery into the brain through intranasal route. Acta Pharm, 58:287–297.
   PubMed Web of Science ®Google Scholar
• Mura P, Maestrelli F, González-Rodríguez ML, Michelacci I, Ghelardini C, Rabasco AM. (2007). Development, characterization and in vivo evaluation of benzocaine-loaded liposomes. Eur J Pharm Biopharm, 67:86–95.
   PubMed Web of Science ®Google Scholar
• Potts RO, Guy RH. (1992). Predicting skin permeability. Pharm Res, 9:663–669.
   PubMed Web of Science ®Google Scholar
• Higuchi T. (1960). Physical chemical analysis of percutaneous absorption from creams and ointments. J Soc Cosmet Chem, 11:85–97.
   Web of Science ®Google Scholar
• Freshney RI. (1994). Culture of Animal Cells, 4th edn. Canada: Wiley-Liss, Inc.
   Google Scholar
• Wang Q, Rager JD, Weinstein K, Kardos PS, Dobson GL, Li J et al. (2005). Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. Int J Pharm, 288:349–359.
   PubMed Web of Science ®Google Scholar
• Kusuhara H, Sugiyama Y. (2005). Efflux transport systems at blood-brain barrier and blood CFS barrier. Int Cong Ser, 1277:111–122.
   Google Scholar
• Borges O, Cordeiro-da-Silva A, Romeijn SG, Amidi M, de Sousa A, Borchard G et al. (2006). Uptake studies in rat Peyer’s patches, cytotoxicity and release studies of alginate coated chitosan nanoparticles for mucosal vaccination. J Control Release, 114:348–358.
   PubMed Web of Science ®Google Scholar
• Degim IT, Gümüsel B, Degim Z, Ozçelikay T, Tay A, Güner S. (2006). Oral administration of liposomal insulin. J Nanosci Nanotechnol, 6:2945–2949.
   PubMed Web of Science ®Google Scholar